Posted by Michael Wonder on 04 Jan 2023
Mobocertinib succinate for patients with advanced EGFR exon 20 insertion mutation positive non-small-cell lung cancer after platinum-based chemotherapy
4 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of mobocertinib succinate in the NHS in England.
Mobocertinib succinate is recommended as an option for the treatment of adults with locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy whose tumours have epidermal growth factor receptor exon 20 insertion mutations.
